Mukul Deoras appointed as Colgate-Palmolive India Chairman

FMCG major Colgate-Palmolive India (CPIL) today said its board has appointed Mukul Deoras as Chairman of the company with effect from September 1, 2018.

He replaces Vinod Nambiar whose resignation as Chairman was announced earlier by the company in a regulatory filing on August 1.

The Board of Directors of the company, through a circular resolution passed on August 27, 2018, has appointed Mukul Deoras as a member and the Chairman of the Board of Directors with effect from September 1, 2018, Colgate-Palmolive India said in a filing to BSE.

Most recently, Deoras served as Chief Marketing Officer of Colgate-Palmolive company since August 2015, CPIL said.

Shares of Colgate-Palmolive India (CPIL) today closed at Rs 1,157.80 on BSE, down 0.95 per cent from the previous close.

  • Related Posts

    ‘Import of Refurbished Medical Devices’ Lobby has reared its Ugly Head

    Domestic Medical Device Leaders cry foul against move to do away with Policy Restrictions New Delhi:  The union government mandarins seem to be at it again, diametrically opposed to Prime…

    Indigenous Robotic Surgery is Mantra for Accessible Cancer Care in India

    Best in Class ‘Made in India’ Surgical Robot is proving Best Bet New Delhi: ‘Made in India’ best in class surgical robot SSiMantra is proving godsend for cancer patients in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise